The Calmer Co International Limited (CCO) Earnings Call Transcript & Summary
November 7, 2025
Earnings Call Speaker Segments
Zane Yoshida
executiveGreetings from Brisbane this morning, and a good afternoon to those of you joining from Sydney and other locations. It's a pleasure to have you with us for the Calmer Company's Q1 FY '26 webinar. Matthew Kowal and I are your presenters today, representing the Calmer Co. Matthew Kowal, as everyone is aware, serves as the Chief Commercial Officer of the company. A warm welcome to all our investors, friends, and stakeholders. Thanks, Matt. I'd like to begin by going back over the strategic pillars of the Calmer Company. Matt, could we advance to Slide 2, please. In the communications we've shared so far regarding the Calmer Co, we refer to the 4 strategic pillars that span the business. The first of these is regional sourcing, together with manufacturing excellence and innovation across the organization. Much of this work operationally sits with management in Fiji. Our second strategic pillar, which we keep updating, is the direct-to-consumer channel within the business, Amazon included. Profitable and scalable retail makes up the third strategic pillar. And the fourth strategic pillar for the business — an exciting one, of course — is the wholesale bulk ingredients channel for the company. I'll go into greater detail on how each pillar has progressed during the quarter before we look more closely, in particular, at the revenue generation pillars across the business, which Matt will address.
Zane Yoshida
executiveOkay, so on strategic pillar 1 — we'll come back to that, Matt, but I'll keep going through the pillar updates for now. Yes, we can proceed. Regarding how strategic Pillar 1 progressed during the quarter, broadly speaking, we're now able to import noble kava variety from Papua New Guinea and the Solomon Islands right across the region, and we're also at an advanced stage of talks with exporters and growers in Vanuatu and Tonga. That gives us greater flexibility when it comes to different product formulas, the raw material inputs, depending on varying chemotype profiles and differing potency levels, as we prepare to launch new product formats and also grow the exciting wholesale channel throughout the business. For example, with certain varieties we're observing in some of our in-house testing, we're seeing different types of kava arriving from regional areas that have more application for daytime use, or other varieties suited to evening use too. So that provides us with that degree of flexibility, as I mentioned, regarding the different types of products we're aiming to bring to market shortly. We've discussed stick packs as the next launch, alongside the tincture format we launched with Amazon USA and our flavored kava shots.
Zane Yoshida
executiveOn the quality front across the supply chain, I'm glad to share as well that Standards Australia has been developing a regional standard for Pacific kava quality, and they've completed the initial research report examining every kava variety among the Pacific-growing nations. And naturally, I'm pleased to report that this is now taking shape, building on earlier announcements in which Pacific heads of government committed to regionalizing Noble kava when it comes to growing, processing, and the export that follows, so it meets international standards. So Standards Australia stepping in to back this initiative on the quality side is really significant, once again, as we lay a foundation for scale and success throughout all Pacific-growing countries. Another update tied to pillar #1 is that we've just finished the HACCP audit for the Fiji facility. We're also making headway on in-house testing capability to further reinforce strategic pillar 1. Again, as we move into more meaningful channels that demand more stringent testing — such as the wholesale channel, working with existing partners like IMCD — having a comprehensive testing capability in-house will be a critical piece of that continued success.
Zane Yoshida
executiveMidway through this month, we're commissioning what's known as GC-MS equipment in Fiji. This will let us get highly accurate results on kava raw materials that come into the factory, and also on the standardized material heading back out to export markets through various channels as well. Innovation keeps moving forward across the business. As I mentioned, we previously announced the stick packs that we're aiming to launch before year-end. And while in the U.S. together last week at SupplySide Global, the team certainly sampled the newest iteration of the stick packs, and we're very excited to take this to the next steps. We've also been working alongside our partners, IMCD, on other innovative new formats that Matt may be able to touch on in his updates covering strategic pillars 2, 3 and 4. Those relate to exciting flavor formats that we might look to bring into the Australian market in the near term. Beyond that, manufacturing excellence through the continued strengthening under strategic pillar 1 with quality — we're looking to bring in outside expertise to complement the quality team in Fiji so we can further strengthen our internal capabilities, particularly as we aim to build momentum with the wholesale channel.
Zane Yoshida
executiveWe're also adding more bench strength in terms of preparedness and readiness, with quality personnel from Fiji. Beyond that, the Fiji Kava Bill is coming along quite well. Only this week, the Fiji government approached us as industry stakeholders seeking input on the draft Kava Bill, following conversations we've had lately at the Australia Fiji Business Forum, where the Minister of Agriculture was present. We're potentially looking at a timeline for reviewing the Kava Bill in March 2026. That's a really significant milestone for the Calmer Company, especially given that we've been a pioneer when it comes to quality and sustainable, traceable, high-quality Noble kava arriving at the factory. It gives us a major competitive edge. What the Kava Bill does, though, is elevate to the next level the compliance expected of exporters, processors and growers. As a result, it guarantees that kava passing through — whether imported into Fiji and turned into finished products, or arriving at our factory as raw material from different provinces — satisfies a high standard of food safety compliance at a minimum prior to being exported from the country.
Zane Yoshida
executiveSo that provides a massive edge for us, since we've held food safety accreditation at this site for 10 years now. And when it comes to the route into the United States specifically, we're also FDA registered and audited sites for dietary supplement exports. That covers the update on strategic pillar 1. Turning more broadly to strategic pillar 2, direct-to-consumer, Amazon included — Matt can go deeper on this shortly, but the real headline items are the launches of our fijikava.com and takimai.com websites. Amazon keeps building very strong momentum, with our tincture formats launched there along with our ready-to-drink flavored kava shots. The main Amazon highlights, especially given the solid work Andy keeps delivering for the business, are that we now have a meaningful split across both FijiKava branded products and Taki Mai branded products. We've taken this to the market in announcements noting that Taki Mai now accounts for a 40% share of our total revenue through that platform. On a broader note, it was exciting to see news last week about kava's uptake in the United States, especially that 1 in 10 Americans have now tried drinking kava in some format or another over the last 12 months.
Zane Yoshida
executiveAnd once more, since Matt has deep knowledge in this space, turning to strategic pillar 3, profitable, scalable retail — we truly delivered an outstanding quarter, and scalable, profitable retail contributed heavily to how well we did in Q1 FY '26. On strategic pillar 4, the team has just come back from the United States after attending SupplySide Global. At that trade show we also displayed our range of formats, including our water extracts and our new high-potency formats, and, more broadly, bulk cava ingredients that we export from Fiji into the United States and also into the Australian market. Once again, Matt will go into greater detail about the enthusiasm surrounding the progress in the wholesale channel. Thanks, Matt. Let's go to Slide #2, please. The key highlights for the Calmer Co really are exceptional sales momentum, and the team is doing an outstanding job across every strategic pillar, which is underpinned by strategic pillar 1, our regional sourcing, manufacturing and innovation capability. Revenue of $2.4 million was achieved for the quarter, up 26% against Q4 FY '25. Net cash outflows came to $596,000, down roughly 39% against Q4 FY '25. Australian sales were, naturally, still a major contributor to the $2.4 million for the quarter, with $1.4 million coming from Australian sales.
Zane Yoshida
executiveThat applies to retail too, along with the direct-to-consumer and wholesale channels. Sales in the U.S. are definitely heading the right way and now account for roughly $936,000 for the quarter, which is up 20% compared with Q4 FY '25. So I'd say the team's main focus is really the road map toward breakeven. And the results we've managed to put together in such a short stretch since Matt came on board and Andy Burger came on board show what we can do internally and how focused we are on getting to breakeven. Thanks, Matt, and I'll hand it over to you for the next slide.
Matthew Kowal
executiveThanks, Zane. As Zane mentioned, this was a really solid performance, and it builds on a great deal of the work done earlier in the year, which set up a clear focus on the 3 channels. The standout performers in the last quarter were really Coles and Woolworths, both from a performance growth standpoint, along with the full rollout of the price change, which has let us generate positive margins in a channel with high brand awareness, delivering growth and also contributing to the bottom line. The other significant activity comes from both a new product and a new channel as we look into wholesale, and in particular the opportunity we've seen firsthand from our recent trip last week to the U.S. SupplySide Global in bulk kava ingredient supply. So what we saw in last quarter's results was really reflected in the level of interest and the leads we were able to garner last week. And that comes from everything from our kava bulk powders and kava water extraction to the new products brought to market with the CO2, which made the bigger contribution to last quarter. I think the interesting element to look at is the opportunity that's now opening up with the U.S.
Matthew Kowal
executiveConsidering we currently have no retail presence in the U.S. and are heavily concentrated on online and wholesale channels, their performance compared with Australian volume is quite remarkable. Much of that is being captured at present via Amazon, with solid, consistent expansion across the year. And as Zane mentioned, I believe we're now positioned in both the U.S. and Australia — but in the U.S., especially with Amazon — such that we have 2 brands contributing strongly, and that puts us in a very strong position as we bring further consumer NPD to market that genuinely appeals to the different target segments that have been identified and are now consuming kava, spanning everything from RTD beverages and stick packs, which sit on our NPD timeline for the near future, through to traditional grind and instant powders, which gives us a chance to genuinely serve all the categories experiencing growth, thanks to the capability our supply chain provides for rapid NPD, while also, clearly, being able to get that into the right categories swiftly alongside the right partners. The second element really fueling U.S. growth is the building of our wholesale operation.
Matthew Kowal
executiveAt the moment, this is especially fueled by our high-potency ingredients—our CO2 extracts—along with building links into bulk powders and expanding water extraction applications across various sub-channels. As I mentioned, the U.S. accounts for 39% of total revenue now. And considering, as I noted at the outset, that retail is just now being explored and evaluated for what lies ahead, we're in a very strong position to capitalize on a market that keeps expanding, along with its interest in Calmer. Zane, I'll hand it back to you…
Zane Yoshida
executiveCash used in operations declined 39% for the quarter. That figure reflects inventory on hand at the close of Q1, which stood at roughly $2 million. We told the market we had closed $700,000 of a two-tranche convertible note with our top 10 shareholders. In addition, we announced a strategic investor in the U.S.A., Applied Food Sciences, which took up a significant portion of that. Some background on Applied Food Sciences: they are a major distributor of food and beverage ingredients. So it's certainly very exciting to have them return to the company, given their historical relationship with the Calmer Co before the IPO, and that complements the capability IMCD brings through our long-standing relationship with them as well. IMCD also has some good news, which we'll cover in the wholesale channel update regarding the high potency formats. So if you look at how our strategy has pivoted since the start of this year, we ended Q2 FY '25 with $2.1 million in revenue. The company's refocus was really on developing and advancing an omnichannel approach. It took us a couple of quarters to realize the benefit of that.
Zane Yoshida
executiveWe've had quite a significant reversal over the past 12 months on that front, recovering from $1.8 million in revenue during Q3 FY '25, then rising to $1.8 million — pardon me, $2.1 million in Q4 FY '25, and now reaching $2.4 million in Q1 FY '26. These are genuinely exciting times for the Calmer Co, arriving at just the right moment as broader interest in kava resurfaces as a safer, healthy substitute for alcohol, and really the management of net cash outflows along with the internal discipline the team is showing as we move toward breakeven. Thank you, Matt.
Matthew Kowal
executiveI'll come back in here. Clearly, retail gave us a strong quarter. A good chunk of that stems from the intensive effort put into securing both Coles and Woolworths for the new pricing. Still, what I view as the genuinely encouraging outcome is that beyond the pricing being accepted, we've also kept growing, which demonstrates the demand for kava within a retail setting. We've collaborated closely with them—Coles especially—to build out a category now and going forward that delivers solid margins and incremental growth for the retailer, while also reflecting the range of sizes available and consumers' desire to treat that retailer as a destination. That, in turn, carries over to Woolworths. Early results on the 50 grams have been strong, and it's often tough to get a single SKU onto a retailer's very crowded shelves. The results so far are quite positive, which puts us in a solid position to hold conversations with them and to show the meaningful growth achieved with Coles through adding the 150 gram, which accounts for over 55% of our retail revenue volume, and really illustrate the chance they have to grow that incremental volume. That leaves us considerably stronger in Australia across retail, and it also provides valuable insight into retail activities and how we might potentially extend those into other markets—whether nearer to home or, as I mentioned, as we begin to look toward <<inaudible>>.
Matthew Kowal
executiveRegarding the wholesale channel, Zane, would you like to say something here before I go into a bit more depth?
Zane Yoshida
executiveRight, absolutely. So once more, I believe this truly capitalizes on the traction created by the earlier market updates regarding the new high-potency formats. And I suppose the encouraging development ahead of SupplySide Global last week, Matt, was IMCD's pledge to bring those new high-potency formats to market, standardized to 30%. We had been — the term I'd use is hamstrung regarding what we could accomplish within the Australian market, and certainly having only the ability to offer a water extract historically there. And selling that into the United States was difficult, given that more high-potency formats were available. So now possessing the ability to widen our range of offerings through the wholesale channel, drawing on our CO2 extraction capability, and to deliver a high-quality, fully traceable, transparent ingredient together with our supply chain and our traceable app as well, is very important. As we build on the momentum in the U.S.A. — I mentioned earlier, Matt, that 1 in 10 Americans have tried kava in some shape or form over the last 12 months. And the demand projected for the category is certainly rising at alarming rates across the next 5 years or so. So we are positioned at the right moment with kava, and the kava resurgence in the United States is very exciting.
Zane Yoshida
executiveLast week in Las Vegas at SupplySide Global, we got the chance to sample a wide range of products. We'll be glad to draw on that as we get a handle on the competitive landscape in this category, and also as we consider new items we plan to launch in the United States to serve the very strong, growing demand we're seeing — demand driven in large part by the fact that kava is a clinically proven ingredient for lowering anxiety and has been sold in Western markets for a very long time. That said, I think the Gen Z trend of moving away from drinking alcohol is also a major driver of demand for kava as a safer, healthier option. So the sampling we did last week was genuinely exciting, Matt, and having seen how many beverage formats are already on the market — whether stand-alone kava ingredients or even kava combined with kratom — the momentum is clearly building. I've never come across such an enormous variety of product offerings. And I can tell you the quality varies a great deal. So I'm very enthusiastic about our next steps here, especially given what we can do with the Calmer Company and a fully traceable ingredient.
Zane Yoshida
executiveAs I mentioned before regarding strategic pillar 1, we're developing capability internally via our own testing, and we're also bolstering the quality team in Fiji by bringing in people with very strong experience to help build that capability too.
Matthew Kowal
executiveCertainly. To kind of underscore the point, the opportunity here was extremely obvious. We'd already spotted it prior to the event <<inaudible>>, and it truly drove the message home to us: 2 key things hold steady at the stand and at the show — people are genuinely seeking a reliable supply, since they've witnessed a real struggle in the market, and that's paired with a genuine grasp of quality, of where it originates, and of traceability. So the market exists and is expanding, clearly, from the consumer angle, which then flows upward into the wholesale side. We're now at a stage where we're carrying out substantial work in pillar 1 that lets us deliver the products with the service these bigger businesses require. And concurrently, we're examining some genuinely smart strategic partnerships, such as the ones we have with ICD, which will let us bring these products to market in the most efficient and swift manner while an opportunity sits right in front of us. So these are truly exciting times. It's one of those market segments that is growing. And clearly, we're building a new product line. So plenty of opportunities, plenty of lessons learned along the way, but we now have some incredible people internally who are second to none in the industry.
Matthew Kowal
executiveLooking ahead across the next 2 quarters or so, our attention will be squarely on what we can observe in the U.S. and through the wholesale channel, and on finding ways to replicate and build on what we achieved during the last quarter.
Zane Yoshida
executiveTo wrap up today's Q1 FY '26 webinar and the updates we shared, we're definitely seeing very strong, tangible movement toward breakeven. When it comes to momentum and worldwide demand for kava, we're in the right place at the right time. We told the market earlier that global kava demand came in at roughly USD 1.6 billion for 2024. Through 2033, our projected growth was 14% CAGR, landing at a market size of about $5.6 billion. That covers the existing markets where we operate, which are mostly intra-Pacific trade, U.S.A., New Zealand and Australia. So plenty of potential upside remains, since only 1 in 10 Americans has tried kava in the last 12 months. And certainly, when we look at falling alcohol consumption in these key markets too, I think drinking in the United States sits at a 93-year low. So kava works as a very nice healthier substitute. And since it's a clinically proven ingredient, again, I'll return to the triangular effect, with less anxiety certainly helping toward better sleep. And the anecdotal feedback coming through our pillars 2, 3 and 4 is definitely pointing to people returning to buy cava again and again because they're sleeping better.
Zane Yoshida
executiveConsumers are loosening up, and they're turning away from alcohol. Those are the main forces driving worldwide kava demand. Our focus hasn't changed from what we've already told the market: we're making real headway toward breakeven, with a record quarter on both the revenue side and in terms of net cash outflows for the business. So it's a really exciting moment. We're eager to show our results in Q2 FY '26 and beyond as we take the next steps toward breakeven for the Calmer Company and past that. On top of that, we released an announcement today about our Chairman transition. We see this as a crucial moment given where the business is focused, with the United States. John Homewood has done a truly outstanding job on the turnaround alongside the team over the last 12 months, strengthening our performance and our internal capability across pillars 2, 3 and 4. But I'm incredibly excited to welcome Jim as Chairman to take the helm and lead us into the United States given his enormous experience. It was so obvious at the show in Vegas last week, Matt, as we tried to walk the show with Jim.
Zane Yoshida
executiveLiterally at 2-minute intervals, people keep pulling him aside to talk. He's genuinely that well liked throughout the whole industry. And in my view he'll be an excellent leader as we drive hard toward really robust expansion in the United States over the months and years ahead. That's it. Thanks.
Zane Yoshida
executiveWe'll also take a few questions. And I'll shift over here since Joe isn't hosting this webinar today, Matt. So I'll read out some of the questions that have come in. And maybe the first one, I'll direct to you. "There's been discussion about higher potency CO2 products being used in the wholesale and nutraceutical market with good success. Are there plans to bring CO2 higher potency products to the direct-to-consumer products or 150 gram packs and RTDs, for example?"
Matthew Kowal
executiveThe straightforward response is yes. We're examining several direct CO2 opportunities to bring to market in patch form, and also introducing it as an ingredient via various RTD formats, stick packs and similar offerings, essentially working out the optimal formulation to deliver the best outcome for the consumer. Such things require time, and we want to be sure we test them properly. Getting it right the first time matters. Still, there is an expectation that something from us will be seen in market.
Zane Yoshida
executiveGreat. Matt, maybe the two of us can take this one together. The question is: what’s going to power growth in the U.S.A.? Over the coming 12 months, will it come from flavored shots, from new retail partners, or from wholesale channels? You go ahead first, and then I’ll add my thoughts.
Matthew Kowal
executiveI suppose the first thing is that we’re really doubling down hard on the channels we’re aligned with. So we’re working diligently to keep the momentum going on Amazon, with Andy Burger doing a really successful job driving that. We’re expanding both brands into truly standalone offerings, adding some really key strategic NPD into them to address what we can see, and a lot of the data coming back shows opportunity, and really to keep establishing ourselves as a market leader in that space. We’ve already gained a few share points in a very short period of time. We’ve now also genuinely split both brands into big viable volumes. So the opportunity on Amazon isn’t diminishing. So there’s a really strong focus there. On wholesale, we’ve only just begun to see the early opportunity there. We’ve also seen the interest from our recent expo work. So that’s an initial one. But I guess probably the one part there that currently isn’t live in the U.S., and that’s that retail opportunity. Yes, that’s something we want to look at. At the same time, yes, we want to look at it very carefully, drawing on our learnings in Australia as well as obviously having someone like Jim Tonkin as a chairman with such great expertise in this space.
Matthew Kowal
executiveWe understand that operating in that channel can be expensive. So our aim is to get it right. And as I mentioned, determining where the strongest opportunity will lie, how we first trial that market, and then how we speed it up and scale it—all of that is part of what we're working on, instead of rushing in without taking a closer look.
Zane Yoshida
executiveYes, absolutely. And I believe that definitely continuing to capitalize on the momentum through the Amazon channel and direct-to-consumer—plus the really exciting wholesale channel, Matt—is, I think, the main near-term priority for the team, with exciting times definitely ahead. The following question was, "What are your top strategic priorities for FY '26, and how will they translate into improved shareholder value and reduced dilution risk?" So allow me to begin with that one. For me, the main strategic priorities are definitely continuing to build on what we've accomplished with the strategic pillars, with a real emphasis on strategic pillar 1. We're engaging with very close strategic partners both in Fiji and regionally to further bolster our supply chain and bring costs down when it comes to the cost per kilo of our raw material ingredient, which affects margin across strategic pillars 2, 3, and 4. This involves no cash outflows or cash investments with these partners that we're currently speaking with. It will be a win-win situation. So we're in advanced discussions with a number of these potential partners to add further strength across these supply chains, both in Fiji and regionally. The other strategic focus for the company really is, as you mentioned, Matt, we're at the very early stages of building out this wholesale channel.
Zane Yoshida
executiveWhat I really like about the wholesale channel is that it doesn’t carry any meaningful direct selling costs, correct? We’ve got highly capable distributors at IMCD with a track record of success, not only in Australia but around the world. So it’s genuinely exciting to have them bring our wholesale ingredients to the U.S. market, especially in a high potency format. We’ve announced that Applied Food Sciences has returned as a strategic investor through the convertible note round. So part of the consideration and the strategic priorities for the Calmer Co is certainly understanding how they could potentially fit into this picture alongside IMCD, building additional capability and driving progress in the U.S. market. Once again, Jim brings a great deal of experience in the United States across ingredients, retail, online and all the rest. People have called him the beverage guru. So beverage formats are also a priority as we take these next steps in the U.S.A. But as Jim puts it, it’s about inch-wide mile deep, right? That means concentrating on one specific area and executing it extremely well. And that’s what the team is looking at doing as we transition into the U.S.A. Again, we’re not scaling back our focus on Australia, but continuing to build momentum here, given the strong work Matt has done over the last few months, while certainly staying very focused on ensuring increased shareholder value, but no dilution from these decisions as well.
Zane Yoshida
executiveWe’ve likely got room for another question or two. “Congrats on all the records set last quarter — revenue, Amazon, retail expenses, and so on. Excellent job by the whole team. One thing people noticed: in earlier quarters, receipts have come in above revenue. This past quarter, receipts relative to revenue fell 15%. What’s the primary driver behind that gap?” Would you like to take that? Or I think it’s — if I can start, Matt — it comes down to lumpiness in the wholesale channel. Orders that arrive via wholesale, large orders. So my answer would be that it’s really the uneven timing of cash receipts, specifically in the wholesale channel portion — but go ahead if you’d like to.
Matthew Kowal
executiveNo, no <<inaudible>>. That's absolutely right, particularly given where in the quarter those come in. We ended the quarter on a strong note, with some sizable wholesale orders flowing in. So it just naturally takes a bit more time than the level we've gotten down to for us to really determine things, I think, together with our retail partners and, of course, online.
Zane Yoshida
executiveYes. The final question reads, "Net cash used in operations have fallen by almost 40% this quarter. Can you keep up with this progress?" So definitely, when we're building out the wholesale channel, we're also examining additional inventory financing support within the business. Thus reducing net cash outflows is a priority for us. However, looking at it, we must weigh this against the inventory build that may be necessary, especially for expanding the wholesale channel, since some of the interest currently coming through — and based on the early engagement we've had in the United States from SupplySide Global — means we'll need to build substantial inventory given our pipeline of interest as we bring products to market to support IMCD and the others involved as well. So yes, it's definitely a priority, but we have to factor in the inventory build that supporting the wholesale channel in particular will require. Let me check whether there's anything else. I believe that's it — perhaps one more, Matt, regarding direct-to-consumer. "There has been some discussion about the Acuity platform coming online soon."
Zane Yoshida
executiveCould you give a bit more detail on what Acuity is, how it will help CCO's sales and marketing, and when it will come online?" I briefly mentioned this in my introduction under strategic pillar 2. We've gone live with takimai.com and fijikava.com. We're certainly taking another look at the marketing side — how best we can convert sales through these platforms, whether that means video content and more. But again, Matt, this is your area, so please feel free to add to this.
Matthew Kowal
executiveYes. No, I think if we look at it functionally, the first step is probably moving onto the Salesforce platform, and particularly moving onto the wholesale channel as well. That gives us the ability to activate markets quite quickly — almost like flipping a switch when it comes to currencies — and then also to streamline a lot of those multi-channel or omnichannel operations through a single source of truth. And when we talk about it now, it's more of a D2C piece, looking at all our brands and creating their own stand-alone properties so they can grow and develop and target the markets, all under a single roof. A business like Acuity and their larger IMS business are built on a huge amount of resource and skills around managing all ends of that funnel. And we will start to see a lot more of the extra bits — that's where we're <<inaudible>> adding into loyalty, understanding VIP treatments and really understanding how we're getting consumers right from the start all the way through their life cycle and maximizing the actual output that we get with them. So all under one roof, and being able to understand how we can then leverage between the 2 brands as we go, and other ones as we bring them to market.
Zane Yoshida
executiveYes, it's exciting. It's also exciting for me to now see a meaningful split between FijiKava and Taki Mai, along with the good work Andy keeps doing with the Amazon platform too, Matt. So that complements direct-to-consumer with the Acuity platform. Exciting times lie ahead. With that, I'll bring today's webinar to a close. Thank you, ladies and gentlemen, for attending. Once again, please feel free to reach out through InvestorHub with any additional questions, and we'll get back to you as best we can in a timely manner to answer your queries. <<foreign_lang>>. Talk soon.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete The Calmer Co International Limited transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to The Calmer Co International Limited earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in The Calmer Co International Limited or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.